Presented as a poster at the American Society for Radiation Oncology (ASTRO) 54th Annual Meeting; October 28-31, 2012; Boston, MA.
The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: Changes in practice patterns after publication of Cancer and Leukemia Group B 9343
Version of Record online: 8 DEC 2014
© 2014 American Cancer Society
Volume 121, Issue 2, pages 188–193, 15 January 2015
How to Cite
Palta, M., Palta, P., Bhavsar, N. A., Horton, J. K. and Blitzblau, R. C. (2015), The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: Changes in practice patterns after publication of Cancer and Leukemia Group B 9343. Cancer, 121: 188–193. doi: 10.1002/cncr.28937
- Issue online: 7 JAN 2015
- Version of Record online: 8 DEC 2014
- Manuscript Accepted: 2 JUN 2014
- Manuscript Received: 24 APR 2014
- breast cancer;
- Cancer and Leukemia Group B (CALGB) 9343;
The Cancer and Leukemia Group B (CALGB) 9343 randomized phase 3 trial established lumpectomy and adjuvant therapy with tamoxifen alone, rather than both radiotherapy and tamoxifen, as a reasonable treatment course for women aged >70 years with clinical stage I (AJCC 7th edition), estrogen receptor-positive breast cancer. An analysis of the Surveillance, Epidemiology, and End Results (SEER) registry was undertaken to assess practice patterns before and after the publication of this landmark study.
The SEER database from 2000 to 2009 was used to identify 40,583 women aged ≥70 years who were treated with breast-conserving surgery for clinical stage I, estrogen receptor-positive and/or progesterone receptor-positive breast cancer. The percentage of patients receiving radiotherapy and the type of radiotherapy delivered was assessed over time. Administration of radiotherapy was further assessed across age groups; SEER cohort; and tumor size, grade, and laterality.
Approximately 68.6% of patients treated between 2000 and 2004 compared with 61.7% of patients who were treated between 2005 and 2009 received some form of adjuvant radiotherapy (P < .001). Coinciding with a decline in the use of external beam radiotherapy, there was an increase in the use of implant radiotherapy from 1.4% between 2000 and 2004 to 6.2% between 2005 to 2009 (P < .001). There were significant reductions in the frequency of radiotherapy delivery over time across age groups, tumor size, and tumor grade and regardless of laterality (P < .001 for all).
Randomized phase 3 data support the omission of adjuvant radiotherapy in elderly women with early-stage breast cancer. Analysis of practice patterns before and after the publication of these data indicates a significant decline in radiotherapy use; however, nearly two-thirds of women continue to receive adjuvant radiotherapy. Cancer 2015;121:188–93. © 2014 American Cancer Society.